Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Julphar
Harvard Business School
Fuji
Express Scripts
Accenture
Citi
Cerilliant
Johnson and Johnson
Daiichi Sankyo

Generated: August 17, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title: Methods for administration of taxol
Abstract:Taxol dosages of about 135 mg/m.sup.2 or greater are administered via infusions of less than 6 hours duration; the method makes it possible to provide taxol infusions on an out-patient basis to patients who do not otherwise require hospitalization. In a preferred embodiment, about 135 mg/m.sup.2 of taxol in a cremaphor emulsion is infused over a 3 hour duration, following patient pretreatment with steroids, antihistamines, and H.sub.2 -receptor antagonists sufficient to prevent fatal anaphylactic-like reactions, and preferably sufficient to reduce the occurrence of severe anaphylactic-like reactions in greater than 90% of patients treated. In an alternative embodiment, between 135 mg/.sup.2 and about 175 mg/m.sup.2 of taxol is provided in a 3-hour infusion, following protreatment to minimize hypersensitivity responses. A method for rechallenging patients with taxol after episodes of acute hypersensitivity reactions is also disclosed, thus enabling patients to continue taxol therapy who would otherwise be deprived of treatment.
Inventor(s): Carretta; Renzo Mauro (Madison, CT), Eisenhauer; Elizabeth (Kingston, CA), Rozencweig; Marcel (Spendford, CT)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:08/544,594
Patent Claims: 1. A method for reducing hematologic toxicity in a cancer patient undergoing Taxol treatment comprising parenterally administering to said patient an antineoplastically effective amount of about 135-175 mg/m.sup.2 taxol over a period of about three hours.

2. A method for reducing both hematologic toxicity and neurotoxicity in a cancer patient undergoing Taxol treatment comprising parenterally administering to said patient an antineoplastically effective amount of about 135 mg/m.sup.2 taxol over a period of about three hours.

3. The method of claim 2, wherein said patient is suffering from solid tumors or leukemias.

4. A method for reducing hematologic toxicity in patients suffering from ovarian cancer and undergoing Taxol treatment for such cancer comprising parenterally administering an antineoplastically effective amount of about 135-175 mg/m.sup.2 taxol over a period of about three hours.

5. A method for reducing both hematologic toxicity and neurotoxicity in a patient suffering from ovarian cancer and undergoing Taxol treatment comprising parenterally administering to said patient an antineoplastically effective amount of about 135 mg/.sup.2 taxol over a duration of about three hours.

6. The method of claim 1, wherein said patient is suffering from solid tumors or leukemias.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
McKinsey
Harvard Business School
Federal Trade Commission
Colorcon
QuintilesIMS
McKesson
Covington
Teva
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot